Ernesto Roldán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ernesto Roldán has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Luisa Maria Villar
Department of Immunology, Hospital Ramón y Cajal, 28034 Madrid, Spain
2 shared publications - Mercedes Espiño
Department of Immunology, Hospital Ramón y Cajal, Madrid, Spain
2 shared publications Alfredo Bootello
Servicio de Inmunología, Hospital Ramón y Cajal, Madrid, and
1 shared publicationAna Moreno
Servicio de Inmunología, Hospital Ramón y Cajal, Madrid, and
1 shared publicationCarmen Cámara
Servicio de Inmunología, Hospital Ramón y Cajal, Madrid, and
1 shared publication- Elena Urcelay
Lab. Genetics and Molecular Bases of Complex Diseases, Health Research Institute of Hospital Clínico San Carlos (IdISSC), Madrid, Spain
1 shared publication
Latest Publications
- 1 January 2014
- Published by Elsevier in Inmunología
- Vol. 33 (1) , 6-10
Marcadores pronósticos en pacientes con gammapatía monoclonal de significado incierto
- 1 January 2014
- Published by Elsevier in Inmunología
- Vol. 33 (1) , 6-10
Marcadores pronósticos en pacientes con gammapatía monoclonal de significado incierto
- 31 October 2010
- Published by Elsevier in Clinical Immunology
- Vol. 137 (1) , 51-59
Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis
- 31 October 2010
- Published by Elsevier in Clinical Immunology
- Vol. 137 (1) , 51-59
Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis
- Open Access
- 2 October 2002
- Published by Wiley in British Journal of Haematology
- Vol. 119 (1) , 70-78
CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression
Summary. Malignant plasma cells (PC) from multiple myeloma (MM) patients characteristically home to the bone marrow (BM). High numbers of tumour cells are found in the peripheral blood (PB) only at end‐stage disease (secondary plasma cell leukaemia, PCL) in a minority of patients. Using flow cytometric and fluorescence in situ hybridization (FISH) analysis, a high percentage of tumoral BM PC from untreated patients was found to express CD106. In addition, these cells also expressed an activated form of CD29, as determined using the CD29 activation reporter monoclonal antibody HUTS‐21. Adhesion‐binding experiments showed that CD106+‐activated CD29+ BM PC from these patients adhered to fibronectin (FN) in a CD29/CD49d‐dependent manner. In contrast, marrow PC from progressive patients and BM or circulating malignant cells from secondary PCL patients expressed lower levels or were negative for CD106 and activated CD29, respectively, with a decreased or zero ability to adhere to FN. The expression of constitutive CD29 and CD49d, however, was similar during disease progression. We conclude that BM myelomatous cells co‐express CD106 and a functionally active form of CD29. Moreover, our results suggest that the loss of expression and/or function of these antigens are associated with the progression of MM and may explain the exit of tumoral cells from the BM.
- 2 October 2002
- Published by Wiley in British Journal of Haematology
- Vol. 119 (1) , 70-78
Open AccessCD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression
Summary. Malignant plasma cells (PC) from multiple myeloma (MM) patients characteristically home to the bone marrow (BM). High numbers of tumour cells are found in the peripheral blood (PB) only at end‐stage disease (secondary plasma cell leukaemia, PCL) in a minority of patients. Using flow cytometric and fluorescence in situ hybridization (FISH) analysis, a high percentage of tumoral BM PC from untreated patients was found to express CD106. In addition, these cells also expressed an activated form of CD29, as determined using the CD29 activation reporter monoclonal antibody HUTS‐21. Adhesion‐binding experiments showed that CD106+‐activated CD29+ BM PC from these patients adhered to fibronectin (FN) in a CD29/CD49d‐dependent manner. In contrast, marrow PC from progressive patients and BM or circulating malignant cells from secondary PCL patients expressed lower levels or were negative for CD106 and activated CD29, respectively, with a decreased or zero ability to adhere to FN. The expression of constitutive CD29 and CD49d, however, was similar during disease progression. We conclude that BM myelomatous cells co‐express CD106 and a functionally active form of CD29. Moreover, our results suggest that the loss of expression and/or function of these antigens are associated with the progression of MM and may explain the exit of tumoral cells from the BM.